MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected ...

The company said Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda ...

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its ...

With U.S. markets hovering near record highs, many investors are turning to dividend-paying stocks as a way to balance growth ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

IO Biotech said on Monday its experimental combination cancer vaccine helped slow the disease's progression in a late-stage ...

Novo Nordisk, GSK and others need to replenish their pipelines to replace drugs coming off patent. In the past, buying a promising biotech required paying a 100% premium. But high interest rates and ...

XTRA:MRK 1 Year Share Price vs Fair Value Explore Merck KGaA's Fair Values from the Community and select yours ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Merck rose 1.17% on a trading day, showcasing a volume of $870M and a 121st rank in activity. Analysts are sending mixed ...

Merck & Co., Inc. (NYSE: MRK) is one of the best depressed stocks to buy in 2025. On August 2, the company completed the ...

Germany’s Merck KGaA (MRK: DE) has reported second quarter earnings that missed analyst expectations. The life sciences company’s earnings before interest, taxes, depreciation and amortization (EBITDA ...